title: Specific molecular and cellular events induced by irradiated X-ray photoactivatable drugs raise the problem of co-toxicities: particular consequences for anti-cancer synchrotron therapy.
abstract: Synchrotrons are capable of producing intense low-energy X-rays that enable the photoactivation of high-Z elements. Photoactivation therapy (PAT) consists of loading tumors with photoactivatable drugs and thereafter irradiating them at an energy, generally close to the K-edge of the element, that enhances the photoelectric effect. To date, three major photoactivatable elements are used in PAT: platinum (cisplatin and carboplatin), iodine (iodinated contrast agents and iododeoxyuridine) and gadolinium (motexafin gadolinium). However, the molecular and cellular events specific to PAT and the radiobiological properties of these photoactivatable drugs are still misknown. Here, it is examined how standard and synchrotron X-rays combined with photoactivatable drugs impact on the cellular response of human endothelial cells. These findings suggest that the radiolysis products of the photoactivatable drugs may participate in the synergetic effects of PAT by increasing the severity of radiation-induced DNA double-strand breaks. Interestingly, subpopulation of highly damaged cells was found to be a cellular pattern specific to PAT. The data show that the efficiency of emerging anti-cancer modalities involving synchrotron photoactivation strongly depends on the choice of photoactivatable drugs, and important series of experiments are required to secure their clinical transfer before applying to humans.
authors.affiliation: INSERM, U836, Institut des Neurosciences, 38043 Grenoble, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Gastaldo
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Bencokova
authors.forename: Catherine
authors.initials: C
authors.lastname: Massart
authors.forename: Aurélie
authors.initials: A
authors.lastname: Joubert
authors.forename: Jacques
authors.initials: J
authors.lastname: Balosso
authors.forename: Anne Marie
authors.initials: AM
authors.lastname: Charvet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Foray
mesh_terms: D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D014965:X-Rays
chemical_list: D000970:Antineoplastic Agents